A Condom Company Is Quietly Becoming a Healthcare Export Story.

$CUPID just delivered a Q1 FY27 number that deserves a closer look. Revenue crossed ₹150 crore, while standalone profit jumped 194% YoY to ₹44.2 crore. But the interesting part isn't the condom business alone. Cupid is expanding into institutional healthcare procurement, IVD kits, female condoms, lubricants and international tenders. Its PFSCM relationship in global healthcare procurement adds another potential growth channel. Management has also raised FY27 revenue guidance to ₹660+ crore. The market sees a personal-care company. The bigger opportunity may be a small Indian healthcare manufacturer becoming a global institutional supplier.